GlassScriptPhysician profile
Matthew Lorenz Brust
NPI 1467447664
$12,204.98
in general payments reported to CMS, 2019-2025
58 companies · $2,524 in 2025
The $2,524 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $228 · 2021: $1,213 · 2022: $1,601 · 2023: $2,005 · 2024: $2,658 · 2025: $2,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,187.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,904.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,194.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,131.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $792.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $770.71 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $619.76 | 2019-2025 | |
| Abbvie INC. | $537.77 | 2021-2025 | Ubrelvy |
| Exact Sciences Corporation | $508.64 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $473.36 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.42 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Astellas Pharma US INC | $392.81 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $287.24 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Merck Sharp & Dohme LLC | $221.63 | 2019-2025 | Lagevrio, Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.57 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $188.74 | 2019-2023 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.